Enliven Therapeutics (NASDAQ:ELVN) Receives Sell (D-) Rating from Weiss Ratings

Key Points

• Enliven Therapeutics (NASDAQ:ELVN) has been reaffirmed a "sell (D-)" rating by Weiss Ratings, indicating negative sentiment about its stock performance.
• Despite the sell rating, several brokerages, including HC Wainwright and Robert W. Baird, issued buy ratings and increased price targets for the stock, reflecting mixed analyst views.
• Enliven reported a quarterly earnings loss of ($0.49) per share, surpassing analyst expectations, while institutional investors hold a significant 95.08% ownership of the company's stock.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Several other brokerages have also recently weighed in on ELVN. HC Wainwright boosted their price target on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd. The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics in a research report on Monday, June 16th. They set a "buy" rating and a $37.00 price target on the stock. Finally, Robert W. Baird upped their target price on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research report on Monday, June 16th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, Enliven Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $41.20.

Enliven Therapeutics Stock Performance

Shares of ELVN stock traded up $0.21 on Wednesday, hitting $20.32. 365,363 shares of the stock traded hands, compared to its average volume of 570,052. The firm's 50-day moving average price is $19.64 and its two-hundred day moving average price is $19.58. The stock has a market capitalization of $1.20 billion, a PE ratio of -10.16 and a beta of 0.85. Enliven Therapeutics has a twelve month low of $13.30 and a twelve month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.04. On average, equities research analysts anticipate that Enliven Therapeutics will post -1.95 EPS for the current fiscal year.

Insider Activity

In related news, COO Anish Patel sold 6,667 shares of the company's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $20.24, for a total transaction of $134,940.08. Following the sale, the chief operating officer directly owned 283,308 shares in the company, valued at approximately $5,734,153.92. This represents a 2.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Samuel Kintz sold 3,700 shares of the stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $20.06, for a total transaction of $74,222.00. Following the completion of the transaction, the chief executive officer owned 915,392 shares in the company, valued at $18,362,763.52. This represents a 0.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 97,567 shares of company stock valued at $1,999,998 over the last three months. 25.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Commodore Capital LP increased its position in Enliven Therapeutics by 0.4% during the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company's stock worth $94,138,000 after purchasing an additional 17,809 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Enliven Therapeutics by 7.8% during the 2nd quarter. Geode Capital Management LLC now owns 882,753 shares of the company's stock valued at $17,711,000 after acquiring an additional 63,580 shares in the last quarter. TCG Crossover Management LLC acquired a new stake in Enliven Therapeutics in the second quarter worth $9,990,000. Duquesne Family Office LLC acquired a new stake in Enliven Therapeutics in the second quarter worth $9,288,000. Finally, Franklin Resources Inc. increased its position in Enliven Therapeutics by 2,029.3% in the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company's stock worth $8,631,000 after buying an additional 410,034 shares during the period. Institutional investors and hedge funds own 95.08% of the company's stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.